Article citationsMore>>

Noda, H., Noguchi, S., Yoshimine, T., Goji, S., Adachi, K., Tamura, Y., Izawa, S., Ebi, M., Yamamoto, S., Ogasawara, N., Funaki, Y., Sasaki, M. and Kasugai, K. (2016) A Novel Potassium-Competitive Acid Blocker Improves the Efficacy of Clarithromycin-Containing 7-Day Triple Therapy against Helicobacter pylori. Journal of Gastrointestinal and Liver Diseases, 25, 283-288.

has been cited by the following article:

• TITLE: Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for Helicobacter pylori

  AUTHORS: Mika Miura, Masahiko Ohtaka, Mitsuhiko Hanawa, Naoki Shimura, Yoshioki Yoda, Sho Suzuki

  KEYWORDS: Vonoprazan, Eradication, Helicobacter pylori, Propensity Score Matching, Gastric Mucosal Atrophy

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.7 No.9, September 28, 2017

  ABSTRACT: Aim: To investigate the factors related to the effect of eradication therapy with vonoprazan for Helicobacter pylori (H. pylori). Methods: We retrospectively reviewed medical records of H. pylori-positive patients who received first-line (40 mg vonoprazan/60 mg lansoprazole or 20 mg rabeprazole, 1500 mg amoxicillin, 400 mg clarithromycin, all 2/day for 7 days) (n = 4118). H. pylori eradication was assessed by the 13C-urea breath test with success defined as a result of H. pylori eradication therapy using vonoprazan was more effective than standard triple therapy with proton pump inhibitor. Gastric mucosal atrophy was associated with treatment success.